Product Description
a plant recombinant human glucocerebrosidase (prGCD) using plant cells as carrier vehicle for Gaucher Disease (Sourced from: https://clinicaltrials.gov/ct2/show/NCT01747980)
Mechanisms of Action:
Novel Mechanism: No
Modality: Coagulation Factor
Route of Administration: N/A
FDA Designation: *
Approval Status: Not Approved
Approved Countries: None
Approved Indications: None
Known Adverse Events: None
Company: Protalix
Company Location: Eastern America
Company CEO:
Additional Commercial Interests: None
Clinical Description
Countries in Clinic:
Active Clinical Trial Count:
Recent & Upcoming Milestones
Highest Development Phases
Phase 2: Gaucher Disease
Trial ID |
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
Latest Trial Update Date |
Data Updated |
|---|---|---|---|---|---|---|---|---|
NCT01747980 |
PB-112-01 | P1 |
Completed |
Gaucher Disease |
2014-01-01 |
2019-03-19 |
Treatments |
|
NCT02107846 |
PB-112-02a | P2 |
Completed |
Gaucher Disease |
2015-12-01 |
2019-03-20 |
Treatments |
Recent News Events
Date |
Type |
Title |
|---|